• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Celcuity Inc.

    6/4/25 4:05:34 PM ET
    $CELC
    Medical Specialities
    Health Care
    Get the next $CELC alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on June 4, 2025

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT

    Under the Securities Act of 1933

     

     

     

    CELCUITY INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   82-2863566

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification Number)

     

    16305 36th Avenue North, Suite 100

    Minneapolis, Minnesota 55446

    (Address of Principal Executive Offices and Zip Code)

     

     

     

    Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan

    Celcuity Inc. 2017 Employee Stock Purchase Plan

    (Full Titles of the Plans)

     

     

     

    Brian F. Sullivan

    Chief Executive Officer

    16305 36th Avenue North, Suite 100

    Minneapolis, MN 55446

    (763) 392-0767

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

    Copies to:

    Jonathan R. Zimmerman Griffin D. Foster

    Faegre Drinker Biddle & Reath LLP

    2200 Wells Fargo Center 90 South Seventh Street

    Minneapolis, MN 55402

    (612) 766-7000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    STATEMENT OF INCORPORATION BY REFERENCE

     

    The purpose of this Registration Statement is to register (i) 3,371,432 additional shares of the registrant’s common stock, par value $0.001 per share (the “Common Stock”), reserved for issuance under the registrant’s Amended and Restated 2017 Stock Incentive Plan, and (ii) 185,716 additional shares of Common Stock reserved for issuance under the registrant’s 2017 Employee Stock Purchase Plan. This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding registration of additional securities, and pursuant to such instruction, the contents of the Registration Statements on Form S-8 (File Nos. 333-221117, 333-238787, 333-253940, 333-256500, 333-265328, 333-270238, 333-271976, and 333-279556) are incorporated herein by reference, except for Item 8, Exhibits.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8. Exhibits.

     

    Exhibit No.   Description
    5.1   Opinion of Faegre Drinker Biddle & Reath LLP
    23.1   Consent of Boulay PLLP
    23.2   Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1)
    24.1   Power of Attorney (included on signature page hereof)
    99.1   Celcuity Inc. 2017 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Registration Statement on Form S-1/A filed on September 12, 2017)
    99.2   Celcuity Inc. Amended and Restated 2017 Stock Incentive Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed on May 16, 2025)
    107   Filing Fee Table

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended (the “Securities Act”), the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota, on June 4, 2025.

     

    CELCUITY INC.  
       
    By: /s/ Brian F. Sullivan  
     

    Brian F. Sullivan

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

     

    The undersigned directors and officers of Celcuity Inc. hereby severally constitute and appoint Brian F. Sullivan and Vicky Hahne as attorneys-in-fact for the undersigned, each of them singly, with full and several power of substitution for, and in the name, place and stead of, the undersigned, to sign and file with the Securities and Exchange Commission under the Securities Act, any and all amendments (including post-effective amendments) and exhibits to this registration statement on Form S-8 (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act) and any and all applications and other documents to be filed with the Securities and Exchange Commission pertaining to the registration of the securities covered hereby, with full power and authority to do and perform any and all acts and things whatsoever requisite and necessary or desirable, hereby ratifying and confirming all that said attorneys-in-fact, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Brian F. Sullivan   Chief Executive Officer (Principal Executive Officer),   June 4, 2025
    Brian F. Sullivan   Director and Chairman    
             
    /s/ Vicky Hahne   Chief Financial Officer (Principal Financial and   June 4, 2025
    Vicky Hahne   Accounting Officer)    
             
    /s/ Lance G. Laing   Chief Science Officer, Vice President and Secretary,   June 4, 2025
    Lance G. Laing   and Director    
             
    /s/ Richard E. Buller   Director   June 4, 2025
    Richard E. Buller        
             
    /s/ David F. Dalvey   Director   June 4, 2025
    David F. Dalvey        
             
    /s/ Leo T. Furcht   Director   June 4, 2025
    Leo T. Furcht        
             
    /s/ Polly A. Murphy   Director   June 4, 2025
    Polly A. Murphy        
             
    /s/ Richard J. Nigon   Director   June 4, 2025
    Richard J. Nigon        

     

     

     

    Get the next $CELC alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CELC

    DatePrice TargetRatingAnalyst
    7/1/2025$30.00Buy
    Stifel
    7/22/2024$29.00Outperform
    Leerink Partners
    2/22/2024$40.00Buy
    Stifel
    12/8/2023$27.00Buy
    H.C. Wainwright
    10/8/2021$50.00Buy
    Canaccord Genuity
    9/7/2021$48.00Buy
    Jefferies
    7/29/2021Outperform
    Cowen
    7/27/2021$50.00Buy
    Needham
    More analyst ratings

    $CELC
    SEC Filings

    See more
    • Celcuity Inc. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Celcuity Inc. (0001603454) (Filer)

      6/30/25 7:10:54 AM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Celcuity Inc.

      S-8 - Celcuity Inc. (0001603454) (Filer)

      6/4/25 4:05:34 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Celcuity Inc.

      8-K - Celcuity Inc. (0001603454) (Filer)

      5/16/25 5:00:15 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib

      • In the Phase 1 portion of the CELC-G-201 clinical trial evaluating gedatolisib plusdarolutamide in men with metastatic castration resistant prostate cancer ("mCRPC"),the six-month radiographic progression free survival ("rPFS") rate was 66% • In a Phase 2 clinical trial of gedatolisib plus trastuzumab-pkrb as 3L+ therapy in patients with HER2+ metastatic breast cancer ("mBC"), the objective response rate ("ORR") was 43% • No patients discontinued gedatolisib due to a treatment-related adverse event ("AE") in either clinical trial MINNEAPOLIS, June 30, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies

      6/30/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences

      MINNEAPOLIS, May 21, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the TD Cowen: 6th Annual Oncology Innovation Summit at 9:30 a.m. ET on Wednesday, May 28, 2025. A live webcast will be available using this weblink: https://wsw.com/webcast/cowen180/celc/1978947; andA fireside chat at the Jefferies Global Healthcare Conference at 7:35 a.m. ET on Thursday, June 5, 2025. A live webc

      5/21/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancerApproximately $206 million in cash, cash e

      5/14/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Buller Richard E gifted 1,079 shares and received a gift of 1,079 shares, decreasing direct ownership by 51% to 1,029 units (SEC Form 4)

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/29/25 4:22:35 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Murphy Polly A.

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/29/25 4:21:17 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Dalvey David

      4 - Celcuity Inc. (0001603454) (Issuer)

      5/21/25 4:49:35 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stifel resumed coverage on Celcuity with a new price target

      Stifel resumed coverage of Celcuity with a rating of Buy and set a new price target of $30.00

      7/1/25 8:17:21 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Leerink Partners initiated coverage on Celcuity with a new price target

      Leerink Partners initiated coverage of Celcuity with a rating of Outperform and set a new price target of $29.00

      7/22/24 7:18:40 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Stifel initiated coverage on Celcuity with a new price target

      Stifel initiated coverage of Celcuity with a rating of Buy and set a new price target of $40.00

      2/22/24 6:21:40 AM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

      SC 13G/A - Celcuity Inc. (0001603454) (Subject)

      11/14/24 5:46:12 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celcuity Inc.

      SC 13G/A - Celcuity Inc. (0001603454) (Subject)

      11/14/24 5:46:16 PM ET
      $CELC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Celcuity Inc.

      SC 13G - Celcuity Inc. (0001603454) (Subject)

      11/14/24 4:26:12 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Financials

    Live finance-specific insights

    See more
    • Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

      The primary completion date of the PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is expected in June 2025 and a topline data readout is anticipated in the third quarter of 2025 Enrollment is ongoing in the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 trial and a topline data readout is anticipated in the fourth quarter of 2025 VIKTORIA-2 Phase 3 trial remains on track to dose its first patient in the second quarter of 2025Initiating a clinical trial collaboration with the Dana Farber Cancer Institute and Massachusetts General Hospital to evaluate gedatolisib in combination with abemaciclib and letrozole in patients with endometrial cancerApproximately $206 million in cash, cash e

      5/14/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call

      MINNEAPOLIS, May 07, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2025 after the market closes on Wednesday, May 14, 2025. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information  To participate in the teleconference, domestic callers should dial 1-800-717-1738 and international callers should dial 1-646-307-1865. A live webcast presentation can also be accessed using this

      5/7/25 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to enroll its first patient in Q2 2025Presented encouraging preliminary overall survival data from the Phase 1b study evaluating gedatolisib in combination with palbociclib and endocrine therapy at the 2024 SABCSApproximately $235.1 million in cash, cash equivalents and short-term investments at end of Q4 2024 expected to fund current clinical development program activities through 2026 Management to host webcast and conference call today, March 31, 2025, at 4:30 p.m. ET MINNEAPOLIS, March 31, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a c

      3/31/25 4:01:00 PM ET
      $CELC
      Medical Specialities
      Health Care

    $CELC
    Leadership Updates

    Live Leadership Updates

    See more
    • Celcuity Appoints Eldon Mayer as Chief Commercial Officer

      MINNEAPOLIS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the appointment of Eldon Mayer as Chief Commercial Officer. Mr. Mayer joins Celcuity with over 30 years of biopharmaceutical commercial experience in companies ranging from early-stage biotechs to full scale pharmaceutical companies across many therapeutic areas, including oncology. "Eldon is an exceptional leader with a proven track record of building commercial organizations from the ground up to support the launch of a biotech company's first drug. His significant commercial experience at multiple bio

      2/20/24 7:05:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Appoints Polly Murphy, D.V.M., Ph.D., to Board of Directors

      Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity's Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for a number of different cancers, today announced the appointment of Polly Murphy, D.V.M., Ph.D. to its Board of Directors."We are delighted to welcome Dr. Murphy to our Board and look forward to leveraging her business development expertise and broad industry experience as we continue to advance our pipeline," said Brian Sullivan, CEO and Co-Founder of Celcuity.Dr. Murphy joins Cel

      9/14/22 9:00:00 AM ET
      $CELC
      Medical Specialities
      Health Care
    • Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development

      MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating patients with cancer, today announced the addition of two senior executives to its corporate management team. Michael Snitkovsky joined Celcuity as VP of Program Management and David Bridge joined as VP of Quality Assurance and Process Development."We are pleased to welcome Michael and David to the Celcuity leadership team. Each brings extensive experience across the biopharmaceutical development spectrum, and each has a fantastic track record," said Brian Sullivan, Celcuity's Chief Executive O

      11/29/21 5:00:00 PM ET
      $CELC
      Medical Specialities
      Health Care